European Heart Journal
Papers 10000
1 page of 1,000 pages (10k results)
#1Shakirat O. Oyetunji (UW: University of Washington)H-Index: 1
#2Catherine M Otto (UW: University of Washington)H-Index: 85
#1Masafumi Ono (National University of Ireland, Galway)H-Index: 5
#2Scot Garg (East Lancashire Hospitals NHS Trust)H-Index: 34
Last. Patrick W. Serruys (Imperial College London)H-Index: 212
view all 0 authors...
1 CitationsSource
#1Filippo Crea (UCSC: Catholic University of the Sacred Heart)H-Index: 103
#1Lale Tokgozoglu (Hacettepe University)H-Index: 58
#2Christian Torp-Pedersen (UCPH: University of Copenhagen)H-Index: 126
1 CitationsSource
#1Carolyn S.P. Lam (NUS: National University of Singapore)H-Index: 78
#2João Pedro Ferreira (University of Lorraine)H-Index: 24
Last. Naveed Sattar (Glas.: University of Glasgow)H-Index: 172
view all 0 authors...
Aims null The aim of this article is to explore the influence of region and race/ethnicity on the effects of empagliflozin in the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction (EMPEROR-Reduced) trial. null Methods and results null Of 3730 patients, 1353 (36.3%) were enrolled in Europe, 1286 (34.5%) in Latin America, 425 (11.4%) in North America, and 493 (13.2%) in Asia; 2629 (70.5%) were White, 257 (6.9%) Black, and 672 (18.0%) Asian. Placebo ...
#1Pieter MartensH-Index: 17
#2Matthias DupontH-Index: 15
Last. Wilfried Mullens (University of Hasselt)H-Index: 44
view all 0 authors...
AIMS Iron deficiency is common in heart failure with reduced ejection fraction (HFrEF) and negatively affects cardiac function and structure. The study the effect of ferric carboxymaltose (FCM) on cardiac reverse remodelling and contractile status in HFrEF. METHODS AND RESULTS Symptomatic HFrEF patients with iron deficiency and a persistently reduced left ventricular ejection fraction (LVEF <45%) at least 6 months after cardiac resynchronization therapy (CRT) implant were prospectively randomize...
1 CitationsSource
#1Mattia Lunardi (National University of Ireland, Galway)H-Index: 1
#2Darren Mylotte (National University of Ireland, Galway)H-Index: 11
Last. Faisal Sharif (National University of Ireland, Galway)H-Index: 18
view all 0 authors...
#1Qian-Qian Chen (CPU: China Pharmaceutical University)H-Index: 2
#2Gaoxiang Ma (CPU: China Pharmaceutical University)H-Index: 13
Last. Pingxi Xiao (Nanjing Medical University)H-Index: 1
view all 0 authors...
Aims null Despite considerable therapeutic advances, there is still a dearth of evidence on the molecular determinants of cardiac hypertrophy that culminate in heart failure. Neuraminidases are a family of enzymes that catalyze the cleavage of terminal sialic acids from glycoproteins or glycolipids. This study sought to characterize the role of neuraminidases in pathological cardiac hypertrophy and identify pharmacological inhibitors targeting mammalian neuraminidases. null Methods and results n...
1 CitationsSource
#1Ivan Oransky (NYU: New York University)H-Index: 12
#2Stephen E. Fremes (Sunnybrook Health Sciences Centre)H-Index: 71
Last. Mario Gaudino (Cornell University)H-Index: 39
view all 0 authors...
Top fields of study
Heart failure
Myocardial infarction
Diabetes mellitus